Use of osteopontin for the treatment and/or prevention of...

Harness for working animal

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S350000

Reexamination Certificate

active

10981737

ABSTRACT:
The invention relates to the use of osteopontin, or of an agonist of osteopontin activity, for treatment or prevention of a neurologic diseases.

REFERENCES:
patent: WO00/37502 (2000-08-01), None
patent: WO00/63241 (2000-10-01), None
patent: WO00/64460 (2000-11-01), None
patent: WO01/24831 (2001-04-01), None
Altschul S F et al, (1990) “Basic Local Alignment Search Tool” J Mol Biol. 215: 403-410.
Barres, B.A., and Raff, M.C. (Dec. 13, 1999). “Axonal Control Of Oligodendrocyte Development”. Journal of Cell Biology. 147(6): 1123-1128.
Barres, B.A., et al. (1993). “Multiple Extracellular Signals Are Required For Long-Term Oligodendrocyte Survival”. Development. 118(1): 283-295.
Bjartmar, C., et al (1999). “Axonal Pathology In Myelin Disorders”. Journal of Neurocytology. 28: 383-395.
Breighton, B and Hayden, MR: S, (Feb. 21, 1981). “Huntington's Chorea” Afr Med J.; 59(8): 250.
Dal Canto, M.C., et al (1995). “Two Models Of Multiple Sclerosis: Experimental Allergic Encephalomyelitis (EAE) and Theiler's Murine Encephalomyelitis Virus (TMEV) Infection. A Pathological And Immunological Comparison”. Microsc. Res. Tech. 32(3): 215-29.
Derynk R. et al., (1980). “Isolation And Structure Of A Human Fibroblast Interferon Gene” Nature 285: 542-547.
Devereux J et al, (1984). “A Comprehensive Set Of Sequence Analysis Programs For The VAX” Nucleic Acids Res, 12(1): 387-395.
Dubois-Dalcq, M., et al. (1999). “The Neurobiology Of X-Linked Adrenoleukodystrophy, A Demyelinating Peroxisomal Disorder”. Trends in Neurosciences 22(1): 4-12.
Dubois-Dalcq, M., and Murray, K. (2000). “Why Are Growth Factors Important In Oligodendrocyte Physiology?” Pathol Biol (Paris) 48(1): 80-86,.
Fernández, P.A., et al. (2000). “Evidence That Axon-Derived Neuregulin Promotes Oligodendrocyte Survival In The Developing Rat Optic Nerve”. Neuron 28(1): 81-90.
Franklin, R.J., and Hinks, G.L. (1999). “Understanding CNS Remyelination: Clues From Developmental And Regeneration Biology”. Journal of Neuroscience Research 58(2): 207-213.
Grantham, (1974). “Amino Acid Difference Formula to Help Explain Protein Evolution”, Science. 185: 862-864.
Grinspan, J.B., et al. (1996). “Re-Entry Into The Cell Cycle Is Required For Bfgf-Induced Oligodendroglial Dedifferentiation And Survival”. Journal of Neuroscience Research. 46(4): 456-464.
Grinspan, J.B., et al (1993). “Trophic Effects Of Basic Fibroblast Growth Factor (bFGF) On Differentiated Oligodendroglia: A Mechanism For Regeneration Of The Oligodendroglial Lineage”. Journal of Neuroscience Research. 36(6): 672-680.
Hajihosseini, M., et al (Dec. 15, 1996). “Origin Of Oligodendrocytes Within The Human Spinal Cord”. Journal of Neuroscience. 16(24): 7981-7994.
Hartung, H.P., et al (1998). “Guillain-Barre Syndrome, CIDP And Other Chronic Immune-Mediated Neuropathies”. Current Opinion in Neurology. 11: 497-513.
Hiremath, M.M., et al (1998). “Microglial/macrophage Accumulation During Cuprizone-Induced Demyelination in C57BL/6 Mice”. Journal of Neuroimmunology. 92(1-2): 38-49.
Ichikawa H, et al (2000). “Osteopontin-Immunoreative Primary Sensory Neurons In The Rat Spinal And Trigeminal Nervous System”, Brain Research. 863(1-2):276-281.
Jung, M., et al (1995). “Lines Of Murine Oligodendroglial Precursor Cells Immortalized By An Activated Neu Tyrosine Kinase Show Distinct Degrees Of Interaction With Axons In Vitro And In Vivo”. European Journal of Neuroscience. 7(6): 1245-1265.
Kiefer et al. (Apr. 25, 1989). “The cDNA And Derived Amino Acid Sequence For Human Osteopontin”. Nucleic Acids Res. 17(8):3306.
Kon S, et al (2000). “Antibodies To Different Peptides In Osteopontin Reveal Complexities In The Various Secreted Forms”. Journal of Cellular Biochemistry. 77(3): 487-498.
Kon S, et al (2002). “Mapping Of Functional Epitopes Of Osteopontin By Monoclonal Antibodies Raised Against Defined Internal Sequences”. Journal of Cellular Biochemistry. 84(2): 420-432.
Kunicki, T.J., et al (1997). “Molecular Determinants of arg-gly-asp Ligand Specificity for b3 Integrins”. Journal of Biological Chemistry. 272(7): 4103-4107.
Lee, et al, (Aug. 20, 1999). “Transient Upregulation Of Osteopontin mRNA In Hippocampus And Striatum Following Global Forebrain Ischemia In Rats”. Neuroscience Letters 271(2):81-84.
Lipton, S. A., and Rosenberg, P. A. (Mar. 3, 1994). “Excitatory Amino Acids As A Final Common Pathway For Neurologic Disorders”. New England Journal of Medicine. 330: 613-22.
Loius, J.C., et al (1992). “CG-4 A New Bipontial Glial Cell Line From Rat Brain, Is Capable Of Differentiating In Vitro Into Either Mature Oligodendrocytes Or Type-2 Astrocytes”. Journal of Neuroscience Research 31: 193-204.
Lubetzki, C., et al, (1993). “Even In Culture, Oligodendrocytes Myelinate Solely Axons”. Proceedings of the National Academy of Sciences of the USA. 90:6820-6824.
Marchionni, M.A., et al, (1999). “Neuregulin In Neuron/Glial Interactions In The Central Nervous System. GGF2 Diminishes Autoimmune Demyelination, Promotes Oligodendrocyte Progenitor Expansion, And Enhances Remyelination”. Advances in Experimental and Medical Biology. 468: 283-295.
Mark et al. (Sep. 1984). “Site-Specific Mutagenesis Of The Human Fibroblast Interferon Gene”. Proc. Natl. Acad. Sci. USA., 81: 5662-5666.
Matthieu, J.M., et al, (1992). “Myelin Gene Expression During Demyelination And Remyelination In Aggregating Brain Cell Cultures”. Journal of Neuroimmunology. 40(2-3): 231-234.
McDonald, J. W., et al, (1998). “Oligodendrocytes From Forebrain Are Highly Vulnerable To AMPA/kainate Receptor-Mediated Excitotoxicity”. Nature Medicine. 4(3): 291-297.
Morell, P., et al, (1998). “Gene Expression In Brain During Cuprizone-Induced Demyelination And Remyelination”. Molecular and Cellular Neurosciences. 12(4/5): 220-227.
Nait-Oumesmar, et al, (1999). “Progenitor Cells Of The Adult Mouse Subventricular Zone Proliferate, Migrate And Differentiate Into Oligodendrocytes After Demyelination”. European Journal of Neuroscience. 11(12): 4357-4366.
Ng, W.P., et al, (1996). “Human Central Nervous System Myelin Inhibits Neurite Outgrowth”. Brain Research. 720(1-2): 17-24.
Noseworthy, J.H. (1999). “Progress In Determining The Causes And Treatment Of Multiple Sclerosis”. Nature. 399: A40-A47.
Oldberg et al., (Dec. 1986) “Cloning And Sequence Analysis Of Rat Bone Sialoprotein (Osteopontin) cDNA Reveals An Arg-Gly-Asp Cell-Binding Sequence”. Proc Natl Acad Sci USA. 83(23):8819-8823.
Pantoni, L., et al, (1996). “Cerebral White Matter Is Highly Vulnerable To Ischemia”. Stroke. 27(9): 1641-1646.
Pearson W R, (1990). “Rapid And Sensitive Sequence Comparison with FASTP and FASTA”. Methods in Enzymology. 183, 63-99.
Pearson W R and Lipman D J, (Apr. 1988). “Improved Tools For Biological Sequence Comparison”. Proc Nat Acad Sci USA. 85: 2444-2448.
Petry, K.G., et al, (2000). “Experimental Allergic Encephalomyelitis Animal Models For Analyzing Features Of Multiple Sclerosis”. Pathologie Biologie. (Paris) 48(1): 47-53.
Pöhlau, D., et al, (1998). “Promoting Remyelination As A Future Therapeutic Principle In Multiple Sclerosis”. Nervenarzt, 69, 841-850.
Prineas, J.W., et al, (1993). “Multiple Sclerosis: Remyelination Of Nascent Lesions”. Annals of Neurology. 33(2): 137-151.
Rodriguez-Peña, A. (1999) “Oligodendrocyte Development And Thyroid Hormone”. Journal of Neurobiology. 40(4): 497-512.
Rogister, B., et al, (1999). “From Neural Stem Cells To Myelinating Oligodendrocytes”. Molecular and Cellular Neurosciences. 14(4-5): 287-300.
Sahrbacher, U.C., et al,

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Use of osteopontin for the treatment and/or prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of osteopontin for the treatment and/or prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of osteopontin for the treatment and/or prevention of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3877515

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.